Top 5 This Week

Related Posts

Tesla sales fall across Europe again as BYD surges; Ryanair to appeal €256m fine from Italy’s competition authority – business live | Business

Key events

Novo Nordisk shares rally after Wegovy pill gets US oral approval

Shares in Novo Nordisk have jumped 7.5% this morning after it won approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally.

Yesterday, US regulators gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

The US Food and Drug Administration’s approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly’s oral drug, orforglipron, is still under review.

That’s a welcome boost to Novo, whose shares have almost halved this year as competition in the weight loss industry has intensified.

Share



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular Articles